title: p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours.
abstract: The status of p53 was investigated in breast tumours arising in germ-line carriers of mutant alleles of BRCA1 and BRCA2 and in a control series of sporadic breast tumours. p53 expression was detected in 20/26 (77%) BRCA1-, 10/22 (45%) BRCA2-associated and 25/72 (35%) grade-matched sporadic tumours. Analysis of p53 sequence revealed that the gene was mutant in 33/50 (66%) BRCA-associated tumours, whereas 7/20 (35%) sporadic grade-matched tumours contained p53 mutation (P<0.05). A number of the mutations detected in the BRCA-associated tumours have not been previously described in human cancer databases, whilst others occur extremely rarely. Analysis of additional genes, p16INK4, Ki-ras and beta-globin revealed absence or very low incidence of mutations, suggesting that the higher frequency of p53 mutation in the BRCA-associated tumours does not reflect a generalized increase in susceptibility to the acquisition of somatic mutation. Furthermore, absence of frameshift mutations in the polypurine tracts present in the coding sequence of the TGF beta type II receptor (TGF beta IIR) and Bax implies that loss of function of BRCA1 or BRCA2 does not confer a mutator phenotype such as that found in tumours with microsatellite instability (MSI). p21Waf1 was expressed in BRCA-associated tumours regardless of p53 status and, furthermore, some tumours expressing wild-type p53 did not express detectable p21Waf1. These data do not support, therefore, the simple model based on studies of BRCA-/- embryos, in which mutation of p53 in BRCA-associated tumours results in loss of p21Waf1 expression and deregulated proliferation. Rather, they imply that proliferation of such tumours will be subject to multiple mechanisms of growth regulation.
authors.affiliation: Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, UK.
authors.forename: T
authors.initials: T
authors.lastname: Crook
authors.forename: L A
authors.initials: LA
authors.lastname: Brooks
authors.forename: S
authors.initials: S
authors.lastname: Crossland
authors.forename: P
authors.initials: P
authors.lastname: Osin
authors.forename: K T
authors.initials: KT
authors.lastname: Barker
authors.forename: J
authors.initials: J
authors.lastname: Waller
authors.forename: E
authors.initials: E
authors.lastname: Philp
authors.forename: P D
authors.initials: PD
authors.lastname: Smith
authors.forename: I
authors.initials: I
authors.lastname: Yulug
authors.forename: J
authors.initials: J
authors.lastname: Peto
authors.forename: G
authors.initials: G
authors.lastname: Parker
authors.forename: M J
authors.initials: MJ
authors.lastname: Allday
authors.forename: M R
authors.initials: MR
authors.lastname: Crompton
authors.forename: B A
authors.initials: BA
authors.lastname: Gusterson
mesh_terms: D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein; D001943:Breast Neoplasms / Q000235:genetics*; D003062:Codon; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins / Q000235:genetics; D005260:Female; D015870:Gene Expression; D006801:Humans; D008938:Mitosis; D009154:Mutation; D009363:Neoplasm Proteins / Q000235:genetics*; D010641:Phenotype; D014157:Transcription Factors / Q000235:genetics*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D019313:BRCA1 Protein; D024682:BRCA2 Protein; C493956:CDKN1A protein, human; D003062:Codon; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D009363:Neoplasm Proteins; D014157:Transcription Factors; D016159:Tumor Suppressor Protein p53